13 results about "Polio virus" patented technology

The invention relates to the field of medicines, and discloses application of doxazosin, thiobis (dichlorophenol) and diclophenol in preparation of medicines for preventing and / or treating enterovirus infection. The inventor finds that doxazosin mesylate, thiobichlorophenol and pharmaceutically acceptable salts or prodrugs thereof have a good inhibition effect on enteroviruses, especially poliovirus type 1, coxsackie virus group A type 9 and enterovirus type A71, and diclophenol has activity of resisting coxsackie virus. The method has an important clinical application value in treatment and prevention of related diseases caused by enterovirus infection.

A production device, method and application of nano-sized zinc molybdate. The device includes a double-cone mixer; an elevator is obliquely provided at a bottom of a discharge port of the double-cone mixer; a rear end of the elevator is located above a feeder; the feeder is connected to one end of an electric heating converter, an other end of the electric heating converter is connected to a finished product bin; a top of the finished product bin is provided with an atomizing nozzle for adding nanomaterial dispersant; the atomizing nozzle is connected to a syringe pump by pipeline. High-purity nano-sized molybdenum trioxide and nano-sized zinc oxide are adopted to synthesize nano-sized zinc molybdate in an electric heating converter. The nano-sized zinc molybdate prepared by the device and method can be used for treatment of African swine fever virus, coronavirus, and AIDS phase I, Ebola, dengue fever, polio viruses.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

This application provides a poliovirus and method for treating human glioma, comprising a composition of oncolytic poliovirus and an Ommaya capsule, a delivery method, and uses.

The invention relates to fast-acting viricidal compositions and methods of using the same, wherein the compositions are capable of removing soil and effectively inactivating a wide variety of viral pathogens, particularly small, non-enveloped viruses such as poliovirus and norovirus. The compositions are especially useful on hard surfaces, and can easily be applied to a service to provide rapid viricidal efficacy.

The invention provides a method for detecting residual blood through object surface disinfection wet tissue, and relates to the technical field of medical environment, medical equipment and equipment surface cleaning detection. After the object surface disinfection wet tissue with the residual blood detection function is used for collecting surface samples of a medical environment, a medical instrument and equipment, the residual blood pollution degree of the surfaces of the medical environment, the medical instrument and the equipment is qualitatively, semi-quantitatively and quantitatively judged according to the color change of the object surface disinfection wet tissue with the residual blood detection function. The semi-quantitative detection calibrator comprises multiple stages of color blocks and subdivision grids, and the residual blood volume is calculated by counting the area proportion of different color blocks through visual inspection; according to the quantitative detection AI rule, wet tissue images are scanned through photography and analysis equipment, software analyzes the mapping relation between pixel RGB values and standard concentration, the method is easy and convenient to operate, large-batch data can be rapidly processed, the cost is remarkably reduced, and the method is particularly suitable for rapid pollution evaluation of medical environments, medical instruments and equipment surfaces. Meanwhile, the pirameton can generate a composite reaction with other components in the object surface disinfection wet tissue with the residual blood detection function, so that the sterilization and disinfection capability of the product is improved; through detection, the killing rate of the object surface disinfection wet tissue with the residual blood detection function on microorganisms such as staphylococcus aureus, escherichia coli and pseudomonas aeruginosa within one minute is as high as 99.999%, and the killing rate of the object surface disinfection wet tissue on poliovirus is as high as 99.99%.

A modified polio virus receptor (PVR / CD155) gene including one or more mutations in exons selected from exons 2, 3 and 4 of poliovirus receptor (PVR / CD155) gene having SEQ ID No.1. More specifically, cell lines including the modified gene and method of producing the same using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) system. The cell line is refractory (non-permissive) to poliovirus and susceptible to most Enteroviruses and many other human viruses. Further, the cell line can be applied in the fields of research, diagnostic and therapy.

The invention relates to the field of medicine, in particular to preparation of poliovirus type 1 thermostable virus-like particles and immunogenicity research of the poliovirus type 1 thermostable virus-like particles. The invention provides a poliovirus type 1 virus-like particle, which is selected from any one of the following: a, a capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP2, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1; the capsid protein of the virus-like particle does not contain or contains a mutant capsid protein fragment sVP4; and b, the capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP0 or a variant thereof, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1 or a variant thereof. According to the application, capsid proteins are connected in series at intervals through an operable element, the VLP is successfully prepared in pichia pastoris through sequence optimization, and the purified VLP is named as an sVLP series. The thermal stability result shows that the thermal stability of the sVLP series is far better than that of the wild type VLP (wtVLP), and the sVLP series can tolerate higher temperature; in addition, animal immune tests show that the immunogenicity of the sVLP series is better, and the neutralizing titer of immune serum of the sVLP series is far higher than that of wtVLP immune serum. In conclusion, the sVLP series is a good candidate strategy for PV1 vaccines.

The invention relates to fast-acting viricidal compositions and methods of using the same, wherein the compositions are capable of removing soil and effectively inactivating a wide variety of viral pathogens, particularly small, non-enveloped viruses such as poliovirus and norovirus. The compositions are especially useful on hard surfaces, and can easily be applied to a service to provide rapid viricidal efficacy.

A replicating oncolytic virus vector is provided having a modified Enterovirus genome (e.g., a Poliovirus, Coxsackievirus or Echovirus genome), wherein the modified Enterovirus genome has one or more copies of one or more miRNA target sequences inserted into the UTR region (e.g., via substitution) and / or in-frame within the coding region of the Enterovirus genome. Also provided are compositions and methods for treating cancer (including for example, lung cancer).

The invention relates to the field of medicine, in particular to preparation of poliovirus type 3 thermostable virus-like particles and immunogenicity research of the poliovirus type 3 thermostable virus-like particles. The invention provides a poliovirus type 3 virus-like particle. The poliovirus type 3 virus-like particle is selected from any one of the following: a, a capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP2, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1; and b, the capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP0 or a variant thereof, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1 or a variant thereof. According to the application, capsid proteins are connected in series at intervals through an operable element, the VLP is successfully prepared in pichia pastoris through sequence optimization, and the purified VLP is named as an sVLP series. The thermal stability result shows that the thermal stability of the sVLP series is far better than that of the wild type VLP (wtVLP), and the sVLP series can tolerate higher temperature; in addition, animal immune tests show that the immunogenicity of the sVLP series is better, and the neutralizing titer of immune serum of the sVLP series is far higher than that of wtVLP immune serum. In conclusion, the sVLP series is a good candidate strategy for PV3 vaccines.

The invention relates to a poliovirus primer combination, a kit and a whole-gene capturing method. The primer combination disclosed by the invention comprises primers with nucleotide sequences as shown in SEQ ID NO: 1-12, and highly conserved regions targeting PV1, PV2 and PV3 viruses, and can be specifically combined with poliovirus RNA (Ribonucleic Acid). Through targeted enrichment, library construction and sequencing signal analysis, efficient capture of the whole genome (about 7400 nucleotides) of the virus can be realized, the capture amplicons cover 99% of the virus sequence, and the virus nucleic acid with the virus load greater than or equal to 1 * 10 < 6 > copies / mL can be detected.